Journal
BRITISH JOURNAL OF CANCER
Volume 108, Issue 12, Pages 2542-2548Publisher
SPRINGERNATURE
DOI: 10.1038/bjc.2013.251
Keywords
CDKN2A; methylation; colorectal cancer; prognosis
Categories
Funding
- National Natural Science Foundation of China [81000887]
- Research Fund for the Doctoral Program of Higher Education of China [20090171120064]
- Medical Scientific Research Foundation of Guangdong Province [B2010077]
Ask authors/readers for more resources
Background: The prognostic value of CDKN2A promoter hypermethylation in colorectal cancer remains controversial. We systematically reviewed the evidence for assessment of CDKN2A methylation in colorectal cancer to elucidate this issue. Methods: Pubmed, Embase and ISI web of knowledge were searched to identify eligible studies to evaluate the association of CDKN2A hypermethylation and overall survival and clinicopathological features of colorectal cancer patients. Combined hazard ratios (HRs) or odds ratios (ORs) with 95% confidence interval (95% CI) were pooled using a random-effects model. Results: A total of 11 studies encompassing 3440 patients were included in the meta-analysis. CDKN2A hypermethylation had an unfavourable impact on OS of patients with colorectal cancer (HR 1.65, 95% CI 1.29-2.11). Subgroup analysis indicated that CDKN2A hypermethylation was significantly correlated with OS in Europe (HR 1.49; 95% CI 1.28-1.74) and Asia (HR 3.30; 95% CI 1.68-6.46). Furthermore, there was a significant association between CDKN2A hypermethylation and lymphovascular invasion (OR 1.68, 95% CI 1.15-2.47), lymph node metastasis (OR 1.68, 95% CI 1.09-2.59) and proximal tumour location (OR 2.09, 95% CI 1.34-3.26) of colorectal cancer. Conclusion: This meta-analysis indicated that CDKN2A hypermethylation might be a predictive factor for unfavourable prognosis of colorectal cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available